Active, not recruitingPhase 2NCT06253923

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

Studying Acute motor axonal neuropathy

Last synced from ClinicalTrials.gov May 2, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: SHINKEI Therapeutics, Inc
Intervention: Amantadine Hydrochloride(drug)
Enrollment: 45 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2024 – 2025

Study locations (13)

Los Angeles General Medical Center, Los Angeles, California, United States
UC Davis Medical Center, Sacramento, California, United States
UF Health Heart and Vascular Hospital, Gainesville, Florida, United States
Tampa General Hospital, Tampa, Florida, United States
Maine Medical Center, Portland, Maine, United States
Wayne State University, Detroit, Michigan, United States
Barnes Jewish Hospital, St Louis, Missouri, United States
Hackensack Meridian Health Jersey Shore University Medical Center, Neptune City, New Jersey, United States
University of New Mexico Hospital, Albuquerque, New Mexico, United States
Department of Neurology, Duke University School of Medicine, Durham, North Carolina, United States
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
McGovern Medical School, University of Texas Health Science Center, Houston, Texas, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Collaborators

Duke Clinical Research Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06253923 on ClinicalTrials.gov

Other trials for Acute motor axonal neuropathy

Additional recruiting or active studies for the same condition.

See all trials for Acute motor axonal neuropathy →

← Back to all trials